rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cartesian Therapeutics, Inc.

RNAC · Nasdaq

Health CareBiotechnologyNot moving yetSynthetic Biology / TechBio

RNAC stood above a rising 150-day average in 13 of the last 52 weekly readings, and has been out of that trend for the last 4 weeks. It is 20.0% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 4
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$206K
Insider sales, 12 months
$517K
Officials’ trades on record
0
Institutions holding
91 (+14)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 13 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$3.5M$0$7.0MNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months1
Sale orders, 12 months3
Buyers · sellers1 · 3
WhoDidSharesTraded
Blaine DavisChief Financial Officersold10,591at $6.826 Jan 2026filed 8 Jan 2026
Milos MiljkovicChief Medical Officersold3,573at $6.826 Jan 2026filed 8 Jan 2026
Carsten BrunnPresident and CEOsold23,766at $6.826 Jan 2026filed 8 Jan 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders91+14 on the quarter
New · exited27 · 13
Reported value$90.2M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
Squarepoint Ops LLCadded · filed 14 Aug 20262,254,619$23.5M+16,133+0.7%
BlackRock, Inc.added · filed 7 Aug 2026819,239$8.5M+220,131+36.7%
683 Capital Management, LLCadded · filed 14 Aug 2026650,000$6.8M+320,000+97.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 2026555,823$5.8M+148,226+36.4%
FMR LLCreduced · filed 13 Aug 2026368,429$3.8M-431,314−53.9%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026356,525$3.7M+92,831+35.2%
AQR CAPITAL MANAGEMENT LLCadded · filed 14 Aug 2026356,456$3.7M+272,436+324.3%
MILLENNIUM MANAGEMENT LLCadded · filed 14 Aug 2026309,887$3.2M+25,570+9.0%
TWO SIGMA INVESTMENTS, LPadded · filed 14 Aug 2026296,293$3.1M+128,980+77.1%
STATE STREET CORPadded · filed 7 Aug 2026249,212$2.6M+48,875+24.4%
31 Mar 2023 – 30 Jun 2026
44688Mar 23Mar 24Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Elizabeth Hoge Company insider10% owner · last 2 Apr 20260 · 0
Murat Kalayoglu Company insider10% owner · last 2 Apr 20260 · 0
Michael Singer Company insiderDirector · last 13 Mar 20260 · 0
Blaine Davis Company insiderChief Financial Officer · last 6 Jan 20260 · 3
Carsten Brunn Company insiderPresident and CEO · last 6 Jan 20260 · 22
Milos Miljkovic Company insiderChief Medical Officer · last 6 Jan 20260 · 5
Emily English Company insiderChief Operations Officer · last 2 Jan 20260 · 2
June Ann Seymour Company insiderChief Accounting Officer · last 2 Jan 20260 · 0
Kemal Malik Company insiderDirector · last 2 Jan 20260 · 0
Nishan M. DeSilva Company insiderDirector · last 2 Jan 20261 · 0
Patrick J. Zenner Company insiderDirector · last 2 Jan 20260 · 0
Timothy A. Springer Company insiderDirector, 10% owner · last 2 Jan 202660 · 0

Same industry

MRNA ModernaLeading+147%
ENTX Entera BioLeading+37%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Return on capital employedFY 2025 · to 31 Dec 2025-50.9%
Share count trendFY 2025 · to 28 Feb 20261.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$125.1M
Free cash flowFY 2025 · to 31 Dec 2025−$79.4M

Analyst forecasts

No analyst forecasts yet.